Transport Mechanisms and Their Pathology-Induced Regulation Govern Tyrosine Kinase Inhibitor Delivery in Rheumatoid Arthritis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Schmidt Lauber, Christian ^a   Harrach, Saliha ^a   Pap, Thomas ^a   Fischer, Meike ^a   Victor, Marion ^a   Heitzmann, Marianne ^a   Hansen, Uwe ^a   Fobker, Manfred ^a   Brand, Stefan Martin ^a   Sindic, Aleksandra ^b   Pavenstädt, Hermann ^a   Edemir, Bayram ^a   Schlatter, Eberhard ^a   Bertrand, Jessica ^a   Ciarimboli, Giuliano ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CARRIER PROTEIN; CYTOKINE; IMATINIB; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MULTIDRUG AND TOXIN EXTRUSION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMETHAMINE; SMALL INTERFERING RNA; THIONEINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL COUNT; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TRANSPORT; DRUG UPTAKE; FIBROBLAST; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; PH; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; BENZAMIDES; CELL LINE; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; HUMANS; HYDROGEN-ION CONCENTRATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; ORGANIC CATION TRANSPORT PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871442132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052247     Document Type: Article

References (29)

1. Grimminger F, Schermuly RT, Ghofrani HA, (2010) Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 9: 956-970.
2. Distler JH, Distler O, (2010) Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 69Suppl 1: i48-i51.
3. Paniagua RT, Robinson WH, (2007) Imatinib for the treatment of rheumatic diseases. Nat Clin Pract Rheumatol 3: 190-191.
4. Akashi N, Matsumoto I, Tanaka Y, Inoue A, Yamamoto K, et al. (2011) Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Mod Rheumatol 21: 267-275.
5. Rosengren S, Corr M, Boyle DL, (2010) Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther 12: R65.
6. Rosenbloom J, Castro SV, Jimenez SA, (2010) Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 152: 159-166.
7. Sandler C, Joutsiniemi S, Lindstedt KA, Juutilainen T, Kovanen PT, et al. (2006) Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 347: 31-35.
8. Kameda H, Ishigami H, Suzuki M, Abe T, Takeuchi T, (2006) Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin Exp Immunol 144: 335-341.
9. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, et al. (2008) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83: 258-264.
10. Thomas J, Wang L, Clark RE, Pirmohamed M, (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 3739-3745.
11. Minematsu T, Giacomini KM, (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10: 531-539.
12. McInnes IB, Schett G, (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429-442.
13. Farr M, Garvey K, Bold AM, Kendall MJ, Bacon PA, (1985) Significance of the hydrogen ion concentration in synovial fluid in rheumatoid arthritis. Clin Exp Rheumatol 3: 99-104.
14. le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, et al. (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53: 313-323.
15. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, et al. (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22: 935-942.
16. Gronowicz G, Hadjimichael J, Richards D, Cerami A, Rossomando EF, (1992) Correlation between tumor necrosis factor-alpha (TNF-alpha)-induced cytoskeletal changes and human collagenase gene induction. J Periodontal Res 27: 562-568.
17. Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, et al. (2004) Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21: 415-428.
18. Li YP, Lecker SH, Chen Y, Waddell ID, Goldberg AL, et al. (2003) TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17: 1048-1057.
19. Kay J, High WA, (2008) Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58: 2543-2548.
20. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E, (2011) New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford) 50: 1542-1550.
21. Bach M, Grigat S, Pawlik B, Fork C, Utermohlen O, et al. (2007) Fast set-up of doxycycline-inducible protein expression in human cell lines with a single plasmid based on Epstein-Barr virus replication and the simple tetracycline repressor. FEBS J 274: 783-790.
22. Grigat S, Fork C, Bach M, Golz S, Geerts A, et al. (2009) The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. Drug Metab Dispos 37: 330-337.
23. Wilde S, Schlatter E, Koepsell H, Edemir B, Reuter S, et al. (2009) Calmodulin-associated post-translational regulation of rat organic cation transporter 2 in the kidney is gender dependent. Cell Mol Life Sci 66: 1729-1740.
24. Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, et al. (2004) Regulation of the human organic cation transporter hOCT1. J Cell Physiol 201: 420-428.
25. Kido Y, Matsson P, Giacomini KM, (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54: 4548-4558.
26. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, et al. (1997) Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 51: 913-921.
27. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, et al. (2005) Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A 102: 5256-5261.
28. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, et al. (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333: 341-350.
29. Widmer N, Beguin A, Rochat B, Buclin T, Kovacsovics T, et al. (2004) Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 803: 285-292.